ACARIZAX Receives Marketing Authorization in France

ALK

today announced that authorities in France, the world's biggest sublingual allergy immunotherapy market, have issued a marketing authorisation for ALK's new house dust mite sublingual allergy immuno-therapy tablet (SLIT-tablet), ACARIZAX(r).  Jens Bager, President and CEO says: "Following the issuance of the marketing authorisation, we can now initiate a dialogue with the authorities to make the house dust mite tablet available to doctors and patients."  ACARIZAX(r) received regulatory approval in 11 European countries last year and is indicated for both allergic rhinitis and allergic asthma in adult patients not well controlled by symptom-relieving medications. ACARIZAX(r) was recently launched in Germany and Denmark.  Moreover, the recent, temporary suspension of production by ALK's main competitor has led to a shortage of supply for many doctors and allergy immunotherapy patients, especially in France. As the suspension continues and more allergy sufferers need to renew their prescriptions, the number of affected